Study validates therapy for aggressive bladder cancer
Model using routine clinical data may predict pancreatic cancer risk
14 February 2022Illicit amphetamine (‘speed’) use linked to 5-fold heightened risk of psychosis
14 February 2022Study validates therapy for aggressive bladder cancer
Findings from a new study led by Yale Cancer Center researchers show enfortumab vedotin is effective in patients with muscle-invasive bladder cancer (MIBC) not eligible for cisplatin chemotherapy. The data is from Cohort H of the Phase 1/b2 EV-103 clinical trial being presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO GU) on February 18, 2022.
